SCHEMBL22798334

SCHEMBL22798334

CC(=O)Nc1cc(C(=O)NCCOc2ccc(C(F)(F)F)cc2F)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.53
KMT2A Q03164 3/20 0.47
RAB9A P51151 1/20 0.47
GPR52 Q9Y2T5 2/20 0.47
MRGPRX4 Q96LA9 2/20 0.44
AAK1 Q2M2I8 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 3/20 0.43
HTT P42858 2/20 0.43
CYP3A4 P08684 1/20 0.43
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 2/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595228 0.91 SCN9A (0.54) SCN9AKMT2ARAB9AGPR52MRGPRX4
SCHEMBL22797763 0.90 SCN9A (0.51) SCN9AKMT2ARAB9AGPR52MRGPRX4
SCHEMBL22797762 0.90 SCN9A (0.67) SCN9AKMT2ARAB9AGPR52MRGPRX4
SCHEMBL22798231 0.89 SCN9A (0.52) SCN9AKMT2ARAB9AGPR52MRGPRX4
SCHEMBL22798317 0.89 SCN9A (0.61) SCN9AGPR52MRGPRX4
SCHEMBL20595167 0.88 GSK3B (0.52) SCN9AGSK3AGSK3BBRAFKDR
SCHEMBL22797915 0.87 SCN9A (0.53) SCN9AKMT2ARAB9AMRGPRX4CYP1A2
SCHEMBL22798313 0.84 SCN9A (0.59) SCN9AGSK3AGSK3BBRAFKDR
SCHEMBL22798297 0.83 SCN9A (0.50) SCN9AGPR52
SCHEMBL20595198 0.83 SCN9A (0.45) SCN9AAAK1CYP3A4GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885KMT2A 1799/4885RAB9A 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.